At the press conference of the joint
prevention and control mechanism of the new coronavirus infection pneumonia
epidemic, Zhao Shitang, deputy secretary-general and press spokesman of the
State-owned Assets Supervision and Administration Commission of the State
Council, said that the central enterprise's anti-epidemic drug
"chloroquine phosphate" accelerated production reserves, general
technology The group's Chinese medicine is stepping up efforts to resume the
production of chloroquine phosphate.
Currently, it is increasing its horsepower
to ensure market supply, and preparations can be produced by the end of
February.
China Resources Group is still increasing reserves based on the
existing inventory of 325,000 boxes of chloroquine related products.
Production of chloroquine phosphate now
Affected by this, the stock price of China Pharmaceutical
(600056) rose sharply on February 18 and hit the daily limit.
It is reported
that chloroquine phosphate is listed as one of the Wuhan epidemic prevention
and control drugs, and China Pharmaceuticals has urgently started its
shareholding company, Chongqing Pharmaceutical Southwest Pharmaceutical No. 2
Factory, to prepare for the resumption of production of chloroquine phosphate.
Currently, the raw materials have been organized and ready for production. Can
be fully supplied.
In addition, on the evening of February 17, Baiyunshan
(600332) announced that its holding subsidiary, Guangzhou Baiyunshan Guanghua
Pharmaceutical Co., Ltd., had received the "Approval of Drug Supplement
Application" for chloroquine phosphate tablets approved and issued by the
Guangdong Provincial Food and Drug Administration.
Effective during the
epidemic period. After the drug has passed the inspection of a batch of
products by the Guangdong Provincial Drug Inspection Institute, it can be
produced on the market according to the batch.
It is reported that Guanghua Pharmaceutical obtained the
registration certificate and production approval of the chloroquine phosphate
tablets approved by the Guangdong Provincial Department of Health in 1977, the
re-registration approval in 2015, and the national drug transfer approval
number in 2002.
Now according to the requirements of relevant laws and
regulations to apply for the resumption of production and obtain "drug
supplement application approval".
Guanghua Pharmaceutical has produced
500,000 chloroquine phosphate tablets and is in the second batch of about
500,000 tablets.
Chloroquine generally refers to chloroquine phosphate
Hydroxychloroquine sulfate is an improved version of chloroquine phosphate,
also known as hydroxychloroquine. It has been on the market as a treatment for
rheumatoid arthritis and other diseases for many years. Its structure and
mechanism of action are similar to chloroquine phosphate, and it has better
safety, so it is widely used in clinical practice to replace chloroquine
phosphate.
In 1999, hydroxychloroquine sulfate "Fanle" produced by
Shanghai Pharmaceuticals was the first to be listed in China.
In the first half
of 2019, Shanghai Pharmaceutical's hydroxychloroquine achieved sales revenue of
384 million yuan (accounting for 0.41% of the company's current revenue), a
year-on-year increase of 19.99% and a market share of 76.67%.
In 2018, the
company's hydroxychloroquine tablet revenue was 620.9 million yuan. On February
3, its wholly-owned subsidiary Shanghai Shangyao Zhongxi Pharmaceutical resumed
production in accordance with the requirements of the Ministry of Industry and
Information Technology.
On February 10, the first batch of 400,000 tablets of chloroquine phosphate was produced
Information from China's clinical trial platform shows that
there are currently only eight domestic approvals for hydroxychloroquine
sulfate, including one listed company Fuan Pharmaceutical (300194).
Fuan
Pharmaceutical is a national key high-tech enterprise mainly engaged in the
research, development, production and sales of monocyclic β-lactams,
penicillins and cephalosporin antibiotic raw materials and preparations.
It is
expected to realize net profit attributable to shareholders of listed companies
in 2019 From 290 million yuan to 295 million yuan, a year-on-year increase of
17.52% -19.54%.
It is understood that many domestic pharmaceutical companies
hold chloroquine phosphate production approvals, but because of the low price
and low demand for this drug, most companies do not produce it. At present, the
above-mentioned large enterprises have resumed production.
Author's Bio
 |
| Dr. Shawna Reason |
Education: MBBS, MD
Occupation: Medical Doctor / Virologist
Specialization: Medical Science, Micro Biology / Virology, Natural Treatment
Experience: 15 Years as a Medical Practitioner
About Me | Linkedin | Quora Profile | Medium Profile | Twitter
Comments
Post a Comment